Pru p 3 acts as a strong sensitizer for peanut allergy in Spain - 28/11/12
Doi : 10.1016/j.jaci.2012.08.038
Gracia Javaloyes, MD a, 
, Maria J. Goikoetxea, MD, PhD a, , Ignacio García Nuñez, MD b, Ana Aranda, PhD b, Maria L. Sanz, MD, PhD a, Miguel Blanca, MD, PhD b, Araceli Diaz Perales, PhD c, Juliana da Souza, BS c, Irene Esparza, PhD d, Victoria del Pozo, MD, PhD e, Ana B. Blazquez, PhD b, Stephan Scheurer, PhD f, Stefan Vieths, PhD f, Marta Ferrer, MD, PhD a 
, Maria J. Goikoetxea, MD, PhD a, , Ignacio García Nuñez, MD b, Ana Aranda, PhD b, Maria L. Sanz, MD, PhD a, Miguel Blanca, MD, PhD b, Araceli Diaz Perales, PhD c, Juliana da Souza, BS c, Irene Esparza, PhD d, Victoria del Pozo, MD, PhD e, Ana B. Blazquez, PhD b, Stephan Scheurer, PhD f, Stefan Vieths, PhD f, Marta Ferrer, MD, PhD a a Department of Allergy and Clinical Immunology, Clinica Universidad de Navarra, Pamplona, Spain
b Research Laboratory for Allergic Diseases, Carlos Haya Hospital–Fundacion IMABIS, Malaga, Spain
c Department Biotecnología, ETSI Montes, Universidad Politécnica de Madrid, Madrid, Spain
d Adjuvant Unit, Department of Pharmacy and Pharmaceutical Technology, and Department of Microbiology, University of Navarra, Pamplona, Spain
e Immunology Department, IIS-Fundación Jiménez-Díaz and CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
f Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, Division of Allergology, Langen, Germany
| Supported by the Health Department of the “Gobierno de Navarra” (grant no. 28/2007), “Instituto de Salud Carlos III” (grant no. PS09/01083), and “Fundación Ramón Areces” and by grant RD07/0064 from the Spanish Research Network on Adverse Reactions to Allergens and Drugs (RIRAAF: Red de Investigación de ReaccionesAdversas a Alérgenos y Fármacos) of the Carlos III Health Institute. |
|
| Disclosure of potential conflict of interest: S. Scheurer has received two or more honoraria from and/or received support for travel from Gilead, Roche Diagnostics, GlaxoSmithKline, Bristol-Myers Squibb, Tibotec, and Abbott. S. Vieths has received honoraria from the Food Allergy Resource and Research Program; has received support from the German Federal Ministry of Health, the German Research Foundation (Deutsche Forschungsgemeinschaft, DVG VI 165/6-1 and GVG VI 165/71), the Research Fund of the German Food Industry (Forschungskreis der Ernährungsindustrie, FEI), Monsanto, Pioneer Hi-Bred International, the European Directorate for the Quality of Medicines and Health Care (EDQM), and the German Federal Ministry for Education and Research; is a member of the Executive Committee of the European Academy of Allergy and Clinical Immunology (EAACI); serves on subcommittees of the International Union of Immunological Societies (IUIS); is a registered expert for the European Agency for the Evaluation of Medicinal Products (EMEA) and the European Pharmacopoeia Commission; is chairman of Technical Committee 275 Working Group 12 “Food Allergens” for CEN (the European Committee for Standardization); and is a member of the Food Allergy Working Group of the Deutsche Gesellschaft für Allergie und Klinische Immunologie (DGAKI). M. Ferrer been supported by grants from the Spanish National Health Institute, the Ramón Areces Foundation, and the state of Navarra. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2012
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 130 - N° 6
P. 1432 - décembre 2012 Retour au numéro
Article précédent
- LRBA gene deletion in a patient presenting with autoimmunity without hypogammaglobulinemia
- Siobhan O. Burns, Helen L. Zenner, Vincent Plagnol, James Curtis, Kin Mok, Michael Eisenhut, Dinakantha Kumararatne, Rainer Doffinger, Adrian J. Thrasher, Sergey Nejentsev
- Infant acetaminophen use associates with early asthmatic symptoms independently of respiratory tract infections: The Copenhagen Prospective Study on Asthma in Childhood 2000 (COPSAC2000) cohort
- Eskil Kreiner-Møller, Astrid Sevelsted, Nadja Hawwa Vissing, Ann-Marie Malby Schoos, Hans Bisgaard
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?